TY  -  
T1  - Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF-kappa B signaling pathways 
SN  -  /  
UR  - http://hdl.handle.net/10138/327297 
T3  -  
A1  - Rahmani, Farzad; Asgharzadeh, Fereshteh; Avan, Amir; Barneh, Farnaz; Parizadeh, Mohammad Reza; Ferns, Gordon A.; Ryzhikov, Mikhail; Ahmadian, Mohammad Reza; Giovannetti, Elisa; Jafari, Mohieddin; Khazaei, Majid; Hassanian, Seyed Mahdi 
A2  -  
PB  -  
Y1  - 2020 
LA  - eng 
AB  - Aims: Rigosertib (RGS) is a PI3K inhibitor that exerts protective effects against tumor progression and cancer-related inflammation. This study was aimed to explore the regulatory effects of RGS on proliferative, pro-fibrotic and inflammatory factors in DSS- induced colitis mice model. Materials and methods: The present study integrates systems and molecular biology approaches to investigate the therapeutic potency of RGS in an experimental model of colitis specifically examining its effects on ... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Rigosertib; Colitis; Inflammation; Fibrosis; PI3K/AKT/NF-kappa B signaling axis; ULCERATIVE-COLITIS; PHASE-I; INHIBITOR; ACTIVATION; MANAGEMENT; 01910.NA; SULFATE; DAMAGE; 3111 Biomedicine; 317 Pharmacy 
N1  -   
PP  -  
ER  -